Short-chain TB-500 is associated with an acetylated seven-residue thymosin beta-4 fragment; analytical identification does not establish the therapeutic effects often inferred from the full-length parent peptide.
Explore the research profileSubmit an unpaid laboratory order request for manual review. Availability and any pending amounts require confirmation.
Catalog quantities are not assay results.
Thymosin beta-4-derived heptapeptide
An analytical paper identified a product labeled TB-500 as Ac-LKKTETQ, the N-terminally acetylated fragment corresponding to residues 17–23 of thymosin beta-4. This seven-residue material differs substantially from the full 43-residue parent. Because TB-500 naming has not consistently mapped to one composition, the short-chain label should be interpreted alongside an explicit sequence and terminal-modification specification.
This reference describes the published literature. Exact supplied form and chemical specifications require product-specific documentation. The studies are linked in Selected literature.
The parent protein participates in actin-monomer binding, but sequence overlap alone does not demonstrate that the isolated fragment retains its binding behavior or downstream effects. The cited fragment-identification study established chemical identity and analytical detectability; it did not demonstrate a therapeutic mechanism, injury recovery, or a clinical effect.
Researchers combined chromatography and high-resolution mass spectrometry to identify an acetylated thymosin fragment in a TB-500 product, then synthesized a matching reference. This supports a specific historical chemical assignment rather than every product using that name. [1]
Biophysical experiments on full-length thymosin beta-4 showed changes in actin conformation and dynamics during binding. Such parent-protein data define useful comparative questions, but cannot establish that the short fragment reproduces the complete binding interaction. [3]
A later analytical investigation found that examined internet products did not consistently match previously described compositions. This illustrates the importance of molecular identification. The paper does not establish the composition of any WYZ material. [2]
Study topics describe the cited models, not established benefits of this catalog material.
The directly relevant publications characterize compounds and naming inconsistencies, rather than testing the fragment in a controlled human efficacy trial. Full-length thymosin research belongs to a separate evidence stream and should retain that distinction.
No tissue-repair benefit, pharmacokinetic profile, or safety conclusion for the short fragment follows from these citations. Establishing a biological role would require experiments on the defined fragment with appropriate parent-peptide and inactive controls, followed by evidence relevant to the intended research endpoint.
Primary studies and clearly identified supporting sources. Each link opens the original record.
Identification of Ac-LKKTETQ and reference synthesis; no therapeutic efficacy experiment.
Characterization of selected internet products; no WYZ batch evidence; final publication 2023, online 2022; not evidence about WYZ composition.
Full-length parent peptide only; supports the distinction between parent-protein mechanism and untested fragment equivalence.
Literature reviewed October 2026. This is a selected research overview, not an exhaustive systematic review. Published findings do not establish the identity, purity, sterility or suitability of any WYZ batch. For laboratory research only; not for human or veterinary use.
Final product specifications and product-specific storage instructions have not been supplied. Review the original documentation and your laboratory’s procedures before obtaining or using the material.
For qualified laboratory researchers. Not for human or veterinary use. Product information is not medical advice or a recommendation for personal use.
What to look for in a COAOther single compounds in the collection.
Metabolic Research
Retatrutide is a synthetic peptide studied for coordinated activation of three metabolic hormone receptors, with human research examining glucose regulation, appetite, body weight and liver fat.
Metabolic Research
MOTS-c is a mitochondrial-derived peptide studied in metabolic signaling and skeletal-muscle adaptation, with experimental interventions supported mainly by cell and animal evidence.
Dermal Research
GHK-Cu is a copper complex of glycyl-histidyl-lysine studied for its effects on extracellular-matrix production and remodeling in experimental tissue-repair systems.
